Cronos Group (CRON) Resumen de Acciones
Cronos Group Inc, una empresa de cannabinoides, se dedica al cultivo, la producción, la distribución y la comercialización de productos de cannabis en Canadá, Israel y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 2/6 |
| Crecimiento futuro | 4/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en CRON a partir de nuestros controles de riesgos.
CRON Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Cronos Group Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | CA$3.77 |
| Máximo en las últimas 52 semanas | CA$4.66 |
| Mínimo de 52 semanas | CA$2.54 |
| Beta | 1.23 |
| Cambio en 1 mes | 3.57% |
| Variación en 3 meses | 4.14% |
| Cambio de 1 año | 35.13% |
| Variación en 3 años | 58.40% |
| Variación en 5 años | -65.12% |
| Variación desde la OPV | 354.22% |
Noticias y actualizaciones recientes
Actualización de narrativa • May 12
CRON: Partial Rescheduling And Brand Execution Will Shape Lean Profit Outlook
Analysts have lifted their fair value estimate for Cronos Group from CA$3.19 to CA$3.45, citing recent initiation with a CA$4.50 price target and the view that branded positioning, a lean cost base, and potentially favorable regulatory shifts could support higher long term profitability and a lower future P/E assumption. Analyst Commentary Recent commentary around Cronos Group has focused on brand strength, cost discipline, and the potential impact of regulatory changes in key markets.Actualización de narrativa • Apr 25
CRON: Partial Rescheduling Hopes Will Test Lean Cost Base Execution
Analysts have raised their Cronos Group price target to CA$4.50, citing expectations for slightly stronger revenue growth, modestly better profit margins, and a lower assumed future P/E, following recent bullish coverage and a favorable view on partial cannabis rescheduling. Analyst Commentary Recent research coverage on Cronos Group has centered on how potential regulatory shifts and brand positioning could influence the company’s path to improved profitability and valuation.
Actualización de narrativa • Apr 11
CRON: Canadian Brand Strength And Lean Cost Base Will Support Future Upside
Analysts have reset their price target for Cronos Group to CA$4.50, reflecting fresh coverage that highlights the company’s established Canadian brands, its focus on scaling revenue with a lean cost base, and cultivation practices that are expected to support profitability trends. Analyst Commentary Recent coverage frames Cronos Group as a company with established Canadian brands and a focus on keeping its cost base lean while scaling revenue.Recent updates
Actualización de narrativa • May 12
CRON: Partial Rescheduling And Brand Execution Will Shape Lean Profit Outlook
Analysts have lifted their fair value estimate for Cronos Group from CA$3.19 to CA$3.45, citing recent initiation with a CA$4.50 price target and the view that branded positioning, a lean cost base, and potentially favorable regulatory shifts could support higher long term profitability and a lower future P/E assumption. Analyst Commentary Recent commentary around Cronos Group has focused on brand strength, cost discipline, and the potential impact of regulatory changes in key markets.Actualización de narrativa • Apr 25
CRON: Partial Rescheduling Hopes Will Test Lean Cost Base Execution
Analysts have raised their Cronos Group price target to CA$4.50, citing expectations for slightly stronger revenue growth, modestly better profit margins, and a lower assumed future P/E, following recent bullish coverage and a favorable view on partial cannabis rescheduling. Analyst Commentary Recent research coverage on Cronos Group has centered on how potential regulatory shifts and brand positioning could influence the company’s path to improved profitability and valuation.Actualización de narrativa • Apr 11
CRON: Canadian Brand Strength And Lean Cost Base Will Support Future Upside
Analysts have reset their price target for Cronos Group to CA$4.50, reflecting fresh coverage that highlights the company’s established Canadian brands, its focus on scaling revenue with a lean cost base, and cultivation practices that are expected to support profitability trends. Analyst Commentary Recent coverage frames Cronos Group as a company with established Canadian brands and a focus on keeping its cost base lean while scaling revenue.Actualización de narrativa • Mar 28
CRON: Lean Cost Base And Brand Execution Will Shape Future Earnings Potential
Analysts have lifted their average price target for Cronos Group to CA$4.50, citing expectations for faster top line expansion, a leaner cost base and stronger profitability potential supported by the company's established Canadian cannabis brands and cultivation practices. Analyst Commentary Recent Street research has framed Cronos Group as a branded cannabis operator with established products in Canada and an emphasis on scaling revenue while keeping operating costs in check.Actualización de narrativa • Mar 13
CRON: Canadian Brand Strength And Rescheduling Shift Will Support Future Upside
Analysts have lifted their CA$ price target on Cronos Group, citing the company's Canadian cannabis brands, expectations for better profitability as revenue grows against a lean cost base, and confidence in its cultivation practices as key supports for the higher valuation range. Analyst Commentary Bullish Takeaways Bullish analysts highlight Cronos Group's portfolio of Canadian cannabis brands as a key support for the higher CA$ valuation range, arguing that strong consumer recognition can help sustain revenue as the company scales.Actualización de narrativa • Feb 27
CRON: Canadian Brand Strength And Rescheduling Shift Will Reshape Risk Reward Profile
Analysts have lifted their fair value estimate for Cronos Group to CA$4.24 from CA$3.95, pointing to higher assumed revenue growth and a lower future P/E multiple. They are factoring in recent bullish coverage highlighting the company’s established Canadian cannabis brands, lean cost base, and cultivation practices.Actualización de narrativa • Feb 13
CRON: Rescheduling Shift Will Expose Execution Risks And Restrain Earnings Upside
Analysts have lifted their CA$ fair value estimate for Cronos Group to CA$3.19, citing Street research that points to slightly higher expected revenue growth, modestly stronger profit margins, and a marginally lower future P/E assumption that together support a more constructive long term outlook. Analyst Commentary While the higher CA$3.19 fair value estimate reflects a more constructive stance on Cronos Group, not all research is leaning in the same direction.Actualización de narrativa • Jan 30
CRON: Rescheduling Shift And Product Expansion Will Shape A Balanced Earnings Outlook
Analysts have raised their price target on Cronos Group by a small amount to reflect updated assumptions for slightly higher revenue growth, a modestly stronger profit margin, and a marginally higher future P/E multiple. Analyst Commentary While some research points to a constructive view on Cronos Group, bearish analysts highlight a set of risks that could limit upside and keep the stock more range bound.Actualización de narrativa • Jan 16
CRON: Rescheduling Policy Shift Will Temper Optimism On Future Earnings Profile
Analysts have raised their price target for Cronos Group to US$3.19 from US$2.90, pointing to updated assumptions around slightly higher discount rates, more conservative revenue growth and a modestly stronger profit margin profile, alongside a similar forward P/E outlook. What's in the News President Trump directed the Attorney General to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act, which directly touches U.S. cannabis policy and mentions Cronos Group among other publicly traded peers in the sector (Marijuana Herald).Artículo de análisis • Dec 13
Cronos Group Inc. (TSE:CRON) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected
Cronos Group Inc. ( TSE:CRON ) shareholders have had their patience rewarded with a 29% share price jump in the last...Actualización de narrativa • Sep 04
GrowCo Capacity And Global Markets Will Unlock Potential
The Consensus Analyst Price Target for Cronos Group has increased to CA$3.95, primarily reflecting a notable rise in the company's Future P/E multiple despite stable revenue growth expectations. What's in the News President Trump is considering reclassifying marijuana as a less dangerous drug, which could ease restrictions and benefit cannabis companies such as Cronos Group (The Wall Street Journal).Artículo de análisis • Aug 15
Cronos Group Inc.'s (TSE:CRON) 26% Share Price Surge Not Quite Adding Up
Cronos Group Inc. ( TSE:CRON ) shareholders would be excited to see that the share price has had a great month, posting...
Nueva narrativa • Apr 30
GrowCo Expansion Will Boost Operations But Strain Cash Flow
Investment in GrowCo and advancements in cannabis genetics are set to improve efficiency, enhance profitability, and strengthen market penetration.Artículo de análisis • May 31
We're Interested To See How Cronos Group (TSE:CRON) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Artículo de análisis • Apr 01
Cronos Group Inc.'s (TSE:CRON) P/S Is Still On The Mark Following 29% Share Price Bounce
The Cronos Group Inc. ( TSE:CRON ) share price has done very well over the last month, posting an excellent gain of...Artículo de análisis • Mar 02
We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Artículo de análisis • Feb 02
Revenues Tell The Story For Cronos Group Inc. (TSE:CRON)
When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...Artículo de análisis • Nov 09
Companies Like Cronos Group (TSE:CRON) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Artículo de análisis • Jul 17
We're Hopeful That Cronos Group (TSE:CRON) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...Artículo de análisis • Jun 20
Cronos Group Inc.'s (TSE:CRON) Earnings Haven't Escaped The Attention Of Investors
When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...Rentabilidad de los accionistas
| CRON | CA Pharmaceuticals | Mercado CA | |
|---|---|---|---|
| 7D | 4.4% | 1.3% | 1.6% |
| 1Y | 35.1% | 45.3% | 33.7% |
Rentabilidad vs. Industria: Los resultados de CRON fueron inferiores a los de la industria Canadian Pharmaceuticals, que obtuvo un rendimiento del 45.3% el año pasado.
Rentabilidad vs. Mercado: CRON superó al mercado Canadian, que obtuvo un rendimiento del 33.7% el año pasado.
Volatilidad de los precios
| CRON volatility | |
|---|---|
| CRON Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 11.6% |
| Market Average Movement | 10.2% |
| 10% most volatile stocks in CA Market | 17.9% |
| 10% least volatile stocks in CA Market | 3.9% |
Precio estable de las acciones: CRON no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado Canadian.
Volatilidad a lo largo del tiempo: La volatilidad semanal de CRON (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| n/a | 610 | Mike Gorenstein | thecronosgroup.com |
Cronos Group Inc, una empresa de cannabinoides, se dedica al cultivo, producción, distribución y comercialización de productos de cannabis en Canadá, Israel e internacionalmente. Ofrece flores secas, pre-rolls, aceites, vaporizadores, comestibles y tinturas de cannabis bajo las marcas Spinach, Lord Jones y PEACE NATURALS. La empresa tiene su sede en Stayner, Canadá.
Resumen de fundamentos de Cronos Group Inc.
| Estadísticas fundamentales de CRON | |
|---|---|
| Capitalización bursátil | CA$1.42b |
| Beneficios(TTM) | -CA$13.05m |
| Ingresos (TTM) | CA$202.50m |
7.0x
Ratio precio-ventas (PS)-108.7x
Ratio precio-beneficio (PE)¿Está CRON sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de CRON | |
|---|---|
| Ingresos | US$146.59m |
| Coste de los ingresos | US$88.19m |
| Beneficio bruto | US$58.40m |
| Otros gastos | US$67.85m |
| Beneficios | -US$9.45m |
Últimos beneficios comunicados
Dec 31, 2025
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.025 |
| Margen bruto | 39.84% |
| Margen de beneficio neto | -6.44% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado CRON a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/24 09:26 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Cronos Group Inc. está cubierta por 16 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Jesse Pytlak | ATB Cormark Historical (Cormark Securities) |
| Vahan Ajamian | Beacon Securities Limited |
| Nadine Sarwat | Bernstein |